Effects of Glucagon-Like Peptide-1 Analogs on Sexuality

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

This placebo-controlled, double-blind crossover study is to evaluate the GLP-1 analogue dulaglutide regarding changes in sexuality, the mood and the reproductive axis in healthy men.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Basel, Switzerland
• Collaborators: Goldschmidt-Jacobson Foundation; Swiss National Science Foundation
• Treatments: Dulaglutide

Criteria

Inclusion Criteria:

• Healthy men with normal weight (BMI 18.5-25kg/m2 or BMI 25.1-30kg/m2 and waist circumference <102cm)

• Written informed consent

• Active sex life (sex with partner or masturbation ≥2x/week)

• Satisfactory sex life

• No Hypogonadism (morning total testosterone ≥12mmol/l)

Exclusion Criteria:

• History of pancreatitis

• History of psychiatric disease (by questioning the participant, also regarding current psychiatric treatment)

• Daily nicotine abuse

• Alcohol consumption (>1 glass/day)

• Substance abuse (as eg cannabis, anabolic steroids, benzodiazepines, opiates, psychostimulants)

• Regular intake of medication at any time